Table 1.
Patient characteristics
| n=46 | % or range | |
| Median age (years, range) | 65 | 33–74 |
| Sex (female/male) | 15/31 | 33/67 |
| Performance status (0/1) | 24/22 | 52/48 |
| Treatment setting | ||
| Adjuvant therapy | 5 | 11 |
| Chemoradiotherapy | 17 | 37 |
| Postsurgical recurrence | 2 | 4 |
| Advanced disease | 22 | 48 |
| Treatment regimen | ||
| CDDP+pemetrexed | 13 | 28 |
| CDDP+vinorelbine | 11 | 24 |
| CDDP+S-1 | 10 | 22 |
| CDDP+etoposide | 7 | 15 |
| CDDP+irinotecan | 3 | 7 |
| CDDP+docetaxel | 1 | 2 |
| CDDP+gemcitabine | 1 | 2 |
| Histology | ||
| Adenocarcinoma | 22 | 48 |
| Squamous cell carcinoma | 6 | 13 |
| NSCLC* | 8 | 17 |
| Small cell carcinoma | 8 | 17 |
| Large cell neuroendocrine carcinoma | 2 | 4 |
| Comorbidities | ||
| Hypertension | 14 | 30 |
| Diabetes mellitus | 4 | 9 |
| Cardiac disease | 2 | 4 |
| Pulmonary disease | 9 | 20 |
| Coadministered medications | ||
| Non-steroidal anti-inflammatory drugs | 10 | 22 |
| Contrast agent | 14 | 30 |
| Serum Cr (mg/dL, median) | 0.7 | 0.42–0.99 |
| Estimated Cr clearance (mL/min, median)† | 89 | 57–173 |
| Calculated eGFR‡ (mL/min 1.73 m2, median) | 80 | 56–138 |
*Non-small cell lung cancer, not otherwise specified.
†Calculated Cr clearance using the Cockcroft-Gault equation.
‡Estimated glomerular filtration rate calculated using Japanese equations.
CDDP, cisplatin; Cr, creatinine; eGFR, estimated glomerular filtrate; S-1, tegafur–gimeracil–oteracil potassium.